[
  {
    "letter_name": "1-party-time-609781-09012020",
    "violated_terms": [
      "The product BetterFly is an unapproved new drug sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. § 355(a)].",
      "The product BetterFly is a misbranded drug under section 502 of the FD&C Act [21 U.S.C. § 352].",
      "The introduction or delivery for introduction of this product into interstate commerce is prohibited under sections 301(a) and (d) of the FD&C Act [21 U.S.C. § 331(a) and (d)].",
      "The claims made on the website regarding BetterFly's ability to mitigate, prevent, treat, diagnose, or cure COVID-19 mislead consumers about the product's safety and effectiveness."
    ],
    "recommendations": [
      "Cease the sale of unapproved and unauthorized products intended for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.",
      "Review and correct all website content, product labels, and promotional materials to ensure compliance with the FD&C Act and avoid misleading representations.",
      "Within 48 hours, provide an email to COVID-19-Task-Force-CDER@fda.hhs.gov detailing the specific steps taken to correct the violations and prevent recurrence.",
      "If unable to complete corrective action within 48 hours, provide a reason for the delay and a timeline for completion.",
      "Immediately cease making claims that the product can prevent, treat, or cure COVID-19 without possessing competent and reliable scientific evidence."
    ]
  },
  {
    "letter_name": "11-11-11-brands-627690-11162022",
    "violated_terms": [
      "Your Mood33 Hemp Infused Herbal Tea products are adulterated under section 402(a)(2)(C)(i) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) [21 U.S.C. 342(a)(2)(C)(i)] because they bear or contain an unsafe food additive.",
      "It is a prohibited act to introduce your Mood33 Hemp Infused Herbal Tea products into interstate commerce under sections 301(ll) and 301(a) of the FD&C Act [21 U.S.C. 331(ll) and 331(a)].",
      "CBD added to conventional food is a food additive under section 201(s) of the FD&C Act [21 U.S.C. 321(s)] and is subject to the provisions of section 409 of the FD&C Act [21 U.S.C. 348].",
      "Food containing an unsafe food additive is deemed adulterated under section 402(a)(2)(C)(i) of the FD&C Act [21 U.S.C. 342(a)(2)(C)(i)].",
      "The introduction of adulterated food into interstate commerce is prohibited under section 301(a) of the FD&C Act [21 U.S.C. 331(a)].",
      "It is a prohibited act under section 301(ll) of the FD&C Act [21 U.S.C. 331(ll)] to introduce or deliver for introduction into interstate commerce any food to which has been added a drug approved under section 505 of the FD&C Act."
    ],
    "recommendations": [
      "Investigate and determine the causes of the violations related to the addition of CBD to your products.",
      "Implement corrective actions to ensure that your Mood33 Hemp Infused Herbal Tea products do not contain CBD or any other unapproved food additives.",
      "Provide a written response to the FDA within fifteen working days detailing the specific steps taken to correct these violations, including documentation.",
      "If unable to complete corrective actions within the specified timeframe, provide a reason for the delay and an estimated completion date."
    ]
  },
  {
    "letter_name": "1-stop-chicken-health-shop-689150-07292024",
    "violated_terms": [
      "Marketing of unapproved new animal drugs violates section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].",
      "Products are misbranded under section 502(o) of the FD&C Act [21 U.S.C. § 352(o)] because they have not been drug listed with FDA.",
      "Products are new animal drugs under section 201(v) of the FD&C Act [21 U.S.C. § 321(v)] because they are not generally recognized as safe and effective.",
      "The introduction of these unapproved and misbranded drugs into interstate commerce violates section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].",
      "The products are considered adulterated under section 501(a)(5) of the FD&C Act [21 U.S.C. § 351(a)(5)] because they are unsafe within the meaning of section 512(a) of the FD&C Act [21 U.S.C. § 360b(a)]."
    ],
    "recommendations": [
      "Investigate and determine the causes of the violations and implement measures to prevent their recurrence.",
      "Ensure that all products are either approved, conditionally approved, or index listed under sections 512, 571, and 572 of the FD&C Act [21 U.S.C. § 360b, 360ccc, and 360ccc-1].",
      "Notify the FDA in writing within fifteen (15) working days of receipt of this letter about the specific steps taken to address the violations, including documentation.",
      "If corrective actions cannot be completed within the specified timeframe, provide reasons for the delay and an estimated completion date."
    ]
  },
  {
    "letter_name": "1-stop-supply-corp-dba-1-stop-vapor-supply-685573-06122024",
    "violated_terms": [
      "The electronic nicotine delivery system (ENDS) and e-liquid products listed on the website are considered tobacco products under section 201(rr) of the FD&C Act [21 U.S.C. § 321(rr)] because they contain nicotine and are intended for human consumption.",
      "The products lack a marketing authorization order as required for new tobacco products under section 910(a) of the FD&C Act [21 U.S.C. § 387j(a)], making them adulterated under section 902(6)(A) of the FD&C Act [21 U.S.C. § 387b(6)(A)] and misbranded under section 903(a)(6) of the FD&C Act [21 U.S.C. § 387c(a)(6)].",
      "The design of the Bad Drip Labs e-liquid products is likely to appeal to youth, which raises concerns about public health and safety, as stated in the letter."
    ],
    "recommendations": [
      "Discontinue the sale and distribution of the ENDS and e-liquid products that lack premarket authorization immediately.",
      "Submit a written response to the FDA within 15 working days detailing actions taken to address the violations, including dates of discontinuation and plans for compliance with the FD&C Act.",
      "Ensure that all tobacco products sold or distributed comply with the FD&C Act and its implementing regulations, including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143."
    ]
  },
  {
    "letter_name": "13-vapor-co-llc-619153-11092021",
    "violated_terms": [
      "Manufacturing and distributing e-liquid products without a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act [21 U.S.C. § 387j(c)(1)(A)(i)].",
      "The 13 Vapor Ripe Strawberry 3mg 20mL e-liquid product is classified as a new tobacco product under section 201(rr) of the FD&C Act [21 U.S.C. § 321(rr)].",
      "The product is adulterated under section 902(6)(A) of the FD&C Act [21 U.S.C. § 387b(6)(A)] because it lacks the required marketing authorization.",
      "The product is misbranded under section 903(a)(6) of the FD&C Act [21 U.S.C. § 387c(a)(6)] due to the absence of required notice or information as mandated by section 905(j) of the FD&C Act [21 U.S.C. § 387e(j)].",
      "Engaging in acts with respect to a tobacco product that results in it being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act [21 U.S.C. § 331(k)].",
      "Failure to provide a required report under section 905(j) of the FD&C Act is a prohibited act under section 301(p) of the FD&C Act [21 U.S.C. § 331(p)]."
    ],
    "recommendations": [
      "Submit a written response to the FDA within 15 working days detailing corrective actions taken to address the violations and a plan for maintaining compliance with the FD&C Act.",
      "Include the dates on which the violative sale and/or distribution of the tobacco products were discontinued."
    ]
  }
]